Bladder Cancer

Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with&nbsp;<em>Targeted Oncology</em>.

In an interview with&nbsp;Targeted Oncology, Arlene Siefker-Radtke, MD, discussed the results from this trial that led to the approval of erdafitinib in patients with locally advanced or metastatic bladder cancer who have progressed on platinum-based chemotherapy. She also explained the impact of this approval in this patient population and next steps planned for this agent.

The FDA has granted an orphan drug designation to MB-102, a CD123-directed CAR T-cell therapy, for the treatment of patients with acute myeloid leukemia.

During an interview with <em>Targeted Oncology</em>, Guru P. Sonpavde, MD highlights the extensive research around checkpoint inhibition and chemotherapy combinations and how these regimens are advancing bladder cancer treatment.

Matthew Galsky, MD, discusses how the phase II HCRN GU14-182 study helps to define the role of switch maintenance therapy in patients with urothelial cancer. The study looked at maintenance with pembrolizumab versus placebo following frontline chemotherapy in patients with metastatic urothelial cancer.

Biologics License Application for enfortumab vedotin has been submitted to the FDA for a potential accelerated approval for use as a treatment for patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

The latest results from the CheckMate 032 trial have found that the combination of nivolumab plushigher-dose ipilimumab improved the objective response rate in heavily pretreated patients with metastatic urothelial carcinoma compared with nivolumab monotherapy or a combined regimen with a lower dose ofipilimumab.

General Cancer

The development of an immune-related adverse event was associated with improved patient response in an FDA analysis of patients with advanced urothelial cancer treated with a PD-1/PD-L1 inhibitor.

Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with&nbsp;high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib.&nbsp;Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.&nbsp;